Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af sikkerheden og effekten af Tapinarof-creme, 1%, hos deltagere i alderen 3 måneder til under 24 måneder med atopisk eksem (Adoring)

6. november 2026 opdateret af: Organon and Co

Et randomiseret, dobbeltblindt, køretøjskontrolleret (periode 1) og åben-etiket (periode 2) fase 3-studie til undersøgelse af sikkerhed og effekt af Tapinarof-creme, 1 % hos børnedeltagere i alderen 3 måneder til < 24 måneder med atopisk eksem

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

187

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2J 7E1
        • Dermatology Research Institute
      • Red Deer, Alberta, Canada, T4P 1K4
        • CARe Clinic (Central Alberta Research Clinic)
    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Dr. Chih-Ho Hong Medical Inc.
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3J 0S9
        • Manitoba Allergy Research Inc.
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 5R3
        • Maritime Dermatology
    • Ontario
      • Burlington, Ontario, Canada, L7L 6W6
        • Halton Pediatric Allergy
      • Hamilton, Ontario, Canada, L8S 1G5
        • Triple A Lab Inc.
      • Niagara Falls, Ontario, Canada, L2H 1C4
        • Allergy Research Canada Inc.
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4V 1R9
        • Dr. Rachel Asiniwasis Medical Professional Corporation
      • Saskatoon, Saskatchewan, Canada, S7K 2C1
        • Skinsense Medical Research
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35209
        • AllerVie Clinical Research
    • Arkansas
      • Bryant, Arkansas, Forenede Stater, 72022
        • Dermatology Trial Associates
    • California
      • Los Angeles, California, Forenede Stater, 90045
        • Dermatology Research Associates
      • Sacramento, California, Forenede Stater, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Forenede Stater, 92123
        • Allergy and Asthma Medical Group and Research Center
      • Thousand Oaks, California, Forenede Stater, 91320
        • Clinical Trials Research Institute
    • Colorado
      • Castle Rock, Colorado, Forenede Stater, 80109
        • Clarity Dermatology
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33486
        • Skin Care Research, LLC.
      • Jacksonville, Florida, Forenede Stater, 32256
        • APEX Clinical Trials
      • Wellington, Florida, Forenede Stater, 33449
        • TruDerm Research
    • Georgia
      • Cumming, Georgia, Forenede Stater, 30040
        • Cleaver Medical Group Dermatology, Inc
    • Idaho
      • Meridian, Idaho, Forenede Stater, 83646
        • Ada West Research
    • Illinois
      • Skokie, Illinois, Forenede Stater, 60077
        • Endeavor Health Clinical Trials Center
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46250
        • Dawes Fretzin Clinical Research Group, LLC
      • Plainfield, Indiana, Forenede Stater, 46168
        • The Indiana Clinical Trials Center, PC
    • Kentucky
      • Bowling Green, Kentucky, Forenede Stater, 42104
        • Equity Medical, LLC
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20850
        • Lawrence J Green, MD LLC
    • Michigan
      • Auburn Hills, Michigan, Forenede Stater, 48326
        • Oakland Hills Dermatology
    • Minnesota
      • New Brighton, Minnesota, Forenede Stater, 55112
        • Minnesota Clinical Study Center
    • Mississippi
      • Ridgeland, Mississippi, Forenede Stater, 39157
        • SKY Integrative Medical Center
    • Missouri
      • Saint Joseph, Missouri, Forenede Stater, 64506
        • MediSearch Clinical Trials
    • Nevada
      • Reno, Nevada, Forenede Stater, 89509
        • Skin Cancer and Dermatology Institute
    • New York
      • Kew Gardens, New York, Forenede Stater, 11415
        • Forest Hills Dermatology Group
      • New York, New York, Forenede Stater, 10012
        • Bobby Buka MD, PC
      • The Bronx, New York, Forenede Stater, 10455
        • Equity Medical, LLC
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27516
        • The University of North Carolina Dermatology and Skin Cancer Center
    • Ohio
      • Fairborn, Ohio, Forenede Stater, 45324
        • Dermatologists of Central States, LLC
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73120
        • Allergy Asthma and Clinical Research Center
    • Oregon
      • Portland, Oregon, Forenede Stater, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health & Science University
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Medical University of South Carolina
      • North Charleston, South Carolina, Forenede Stater, 29420
        • National Allergy and Asthma Research, LLC.
    • Texas
      • Bellaire, Texas, Forenede Stater, 77401
        • The University of Texas Health Science Center at Houston
      • Dallas, Texas, Forenede Stater, 75230
        • Dermatology Treatment and Research Center
      • Southlake, Texas, Forenede Stater, 76092
        • Stryde Research - Epiphany Dermatology
    • Washington
      • Spokane, Washington, Forenede Stater, 99202
        • Dermatology Specialists of Spokane

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

3 måneder til 1 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
  • Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
  • Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
  • Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion Criteria:

  • Significant neurological disorder or history of seizure
  • Know clinically significant cardiac rhythm or cardiac disorder
  • History of sudden infant death in a sibling
  • Clinically significant chromosome abnormality
  • History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
  • Diseases that could cause pruritic and/or sleep disruption
  • Immunocompromised
  • Current chronic or acute infection requiring treatment
  • Use of prohibited medication(s) or procedure(s)
  • Use of prohibited medications by breastfeeding mother if breastfeeding participant

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Tapinarof cream

Tapinarof cream, 1%, applied topically once daily

Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

Andre navne:
  • DMVT-505
  • OG-0505
  • GSK2894512A
  • GSK28994512
  • STI-1001
  • WBI-1001
Placebo komparator: Vehicle cream

Vehicle cream is applied topically once daily for up to 8-weeks.

Applied topically once daily to lesions on participant's skin during the Double-Blind period.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Tidsramme: Baseline to the end of the Open-Label Period, up to 56 weeks.

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to the end of the Open-Label Period, up to 56 weeks.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to the end of the Open-Label Period, up to 56 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to the end of the Open-Label Period, up to 56 weeks.

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Tidsramme: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tidsramme: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Tidsramme: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Lead Late-Stage Clinical Development, Organon and Co

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. december 2025

Primær færdiggørelse (Anslået)

1. august 2027

Studieafslutning (Anslået)

1. august 2027

Datoer for studieregistrering

Først indsendt

21. november 2025

Først indsendt, der opfyldte QC-kriterier

2. december 2025

Først opslået (Faktiske)

4. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • OG0505-3104

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .